BeOne Medicines

Company in Cambridge, Massachusetts, USA.

Texto em inglês

BeOne Medicines, formerly known as BeiGene, Ltd. is a multinational oncology company. It specializes in the development of drugs for cancer treatment.

Último preço

—

Preço mínimo

—

Mediana 7 d

—

Vendas 30 d

Faixa 30 d

—

Em circulação

Cotação

Ver tabela

Data	mediana	Mín	Máx	vendas

Histórico de vendas

Última venda: —
Média 30 d: —
Mínima 30 d: —
Máxima 30 d: —
Vendas 7 d: 0
Vendas 30 d: 0

Ainda sem vendas.

Vendas anônimas: sem comprador nem vendedor. Os números contam só vendas entre jogadores.

Na Wikipédia

Texto em inglês Ainda não há artigo no seu idioma: trecho em inglês.

BeOne Medicines, formerly known as BeiGene, Ltd. is a multinational oncology company. It specializes in the development of drugs for cancer treatment. Founded in 2010 by chief executive officer John V. Oyler and Xiaodong Wang, the company is headquartered in Cambridge, Massachusetts and has locations on six continents, in over 45 countries. BeOne has a large presence in the Chinese market. BeOne Medicines has developed several medicines, including tislelizumab (brand name of Tevimbra), a checkpoint inhibitor, and zanubrutinib (brand name of Brukinsa), a Bruton's tyrosine kinase inhibitor. On 14 November 2024, the company announced its intention to rebrand as BeOne Medicines. BeOne changed its stock ticker to ONC in January 2025 and redomiciled to Basel, Switzerland in May 2025.

Texto: Wikipédia em inglês, CC BY-SA 4.0. ·